Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
The group’s B7-H3 ADC looks competitive versus rival projects from Merck/Daiichi and GSK/Hansoh.
The company’s HIF-2α inhibitor impresses on efficacy, but its long half life raises eyebrows.
Having failed to get Zynyz approved in the second-line setting the group has the front line in its sights.
Prelude’s SMARCA2 project and C4’s BRAF hopeful look lacklustre.
Backed by a slender survival signal the industry’s only anti-fucosyl-GM1 MAb is to go pivotal.
Early data suggest that PD-(L)1 x VEGF bispecifics might challenge Keytruda in triple-negative disease.